Trial Registration: ClinicalTrials.gov: BIA-2093-110 NCT01679002.
Full-Length Original Research
Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers
Version of Record online: 12 JUN 2013
Wiley Periodicals, Inc. © 2013 International League Against Epilepsy
Volume 54, Issue 8, pages 1453–1461, August 2013
How to Cite
Elger, C., Bialer, M., Falcão, A., Vaz-da-Silva, M., Nunes, T., Almeida, L. and Soares-da-Silva, P. (2013), Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia, 54: 1453–1461. doi: 10.1111/epi.12242
- Issue online: 30 JUL 2013
- Version of Record online: 12 JUN 2013
- Manuscript Accepted: 1 MAY 2013
- BIAL – Portela & Cª, S.A.
|epi12242-sup-0001-DataS1.docx||Word document||116K||Data S1. Population and Methods (participants and interventions) and Results (study population).|
|epi12242-sup-0002-TableS1-S4.docx||Word document||102K|| |
Table S1. Randomization table.
Table S2. Treatment allocations.
Table S3. Main demographic characteristics.
Table S4. Number of subjects (%) reporting treatment-emergent adverse events (TEAEs) following a repeated-dose regimen of eslicarbazepine acetate (ESL) and oxcarbazepine (OXC).
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.